Sep 7, 2022 | Press Releases
CUPERTINO, Calif., Sept. 07, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Sep 6, 2022 | Press Releases
CUPERTINO, Calif., Sept. 06, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Aug 15, 2022 | Press Releases
– Enrollment on pace for ongoing pivotal Phase 3 RECOVER trial – – Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023 – – $19.4 Million in Cash as of June 30, 2022 – CUPERTINO, Calif., Aug. 15,...
Jul 27, 2022 | Press Releases
Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at sites in Europe and India in Q3 2022 More than 20% of the approximately 400 patients planned for Phase 3...
Jun 2, 2022 | Press Releases
CUPERTINO, Calif.,, June 02, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
May 17, 2022 | Press Releases
CUPERTINO, Calif., May 17, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
